Teva Pharmaceutical Industries (TEVA) Long-Term Deferred Tax (2014 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Long-Term Deferred Tax for 13 consecutive years, with $2.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Deferred Tax rose 21.39% year-over-year to $2.2 billion; the trailing twelve-month figure through Jun 2026 stood at $2.2 billion (up 21.39% YoY), and the FY2025 full-year result was $2.2 billion, up 21.79% from the prior year.
• Long-Term Deferred Tax declined to $2.2 billion in Q2 2026 per TEVA's latest filing, from $2.2 billion in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $2.2 billion in Q4 2025 and bottomed at $637.0 million in Q1 2022.
• Historically, Long-Term Deferred Tax has averaged $1.8 billion across 5 years, with a median of $1.8 billion in 2025.
• The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax soared 148.55% in 2022, then retreated 21.06% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $1.5 billion in 2022, then advanced by 24.28% to $1.8 billion in 2023, then slipped by 0.72% to $1.8 billion in 2024, then increased by 21.79% to $2.2 billion in 2025, then retreated by 1.32% to $2.2 billion in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $2.2 billion, $2.2 billion, and $2.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.